BioCentury
ARTICLE | Company News

Genocea, Checkmate deal

December 16, 2016 9:34 PM UTC

The companies partnered non-exclusively to use Genocea's ATLAS antigen identification screening system to profile about 20 advanced melanoma patients’ T cell responses in Checkmate’s Phase Ib trial of...